A region on chromosome 14q32.1 is often involved in chromosomal translocations and inversions with one of the T-cell receptor loci in T-cell lymphoproliferative diseases. The breakpoints of the dierent rearrangements segregate into two clusters; a cluster due to inversion on the centromeric side and a cluster due to simple balanced translocations on the telomeric side. If the target gene activated by these dierent types of chromosomal rearrangements is the same, the gene must be localized between the two clusters of breakpoints in a region of around 160 kb. Within this breakpoint cluster region, we isolated two genes; namely, TCL1 and TML1/TCL1b genes. In the course of characterizing the TML1 gene, we further identi®ed a third novel gene, which we named TCL6 (T-cell leukemia/lymphoma 6), from a region 7 kb upstream of the TML1 locus. The TCL6 gene expressed at least 11 isoforms through very complex alternativesplicing, including splicing with the TML1 gene. Those isoforms encode at least ®ve open reading frames (ORFs) with no homology to known sequences. The localization of the proteins corresponding to these ORF was determined by fusing green¯uorescence protein at the carboxyl terminal of each ORF. ORF141 and ORF72 were observed in the cytoplasmic region, while ORF105, ORF119, and ORF163 were predominantly localized in the nuclear region. Since the TCL6 gene was expressed in T-cell leukemia carrying a t(14;14) (q11;q32.1) chromosome translocation and was not expressed in normal T-cells (just like the TML1 and TCL1 genes), it is also a candidate gene potentially involved in leukemogenesis.
A region on chromosome 14q32.1 is often involved in chromosomal translocations and inversions with one of the T-cell receptor loci in T-cell lymphoproliferative diseases. The breakpoints of the dierent rearrangements segregate into two clusters; a cluster due to inversion on the centromeric side and a cluster due to simple balanced translocations on the telomeric side. If the target gene activated by these dierent types of chromosomal rearrangements is the same, the gene must be localized between the two clusters of breakpoints in a region of around 160 kb. Within this breakpoint cluster region, we isolated two genes; namely, TCL1 and TML1/TCL1b genes. In the course of characterizing the TML1 gene, we further identi®ed a third novel gene, which we named TCL6 (T-cell leukemia/lymphoma 6), from a region 7 kb upstream of the TML1 locus. The TCL6 gene expressed at least 11 isoforms through very complex alternativesplicing, including splicing with the TML1 gene. Those isoforms encode at least ®ve open reading frames (ORFs) with no homology to known sequences. The localization of the proteins corresponding to these ORF was determined by fusing green¯uorescence protein at the carboxyl terminal of each ORF. ORF141 and ORF72 were observed in the cytoplasmic region, while ORF105, ORF119, and ORF163 were predominantly localized in the nuclear region. Since the TCL6 gene was expressed in T-cell leukemia carrying a t(14;14) (q11;q32.1) chromosome translocation and was not expressed in normal T-cells (just like the TML1 and TCL1 genes), it is also a candidate gene potentially involved in leukemogenesis.
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Keywords: chromosome 14q32; T-cell leukemia; TML1; TCL1; MTCP-1; translocation In T-cell tumors, the T-cell receptor (TCR) genes located on chromosomes 14q11 (TCRA/D) (Isobe et al., 1988) , 7q35 (TCRB) (Isobe et al., 1985) and 7p15 (TCRG) (Murre et al., 1985) , occasionally cause translocations or inversions as a consequence of the faulty joining of genes during the physiological process leading to VDJ recombination. These rearrangements juxtapose enhancer elements of the TCR genes next to oncogenes, whose expression is then deregulated (Croce, 1987) . Chromosome region 14q32.1 is commonly involved in chromosomal rearrangements with TCR loci in several T-cell neoplasms, as shown in Figure 1 . Chromosome abnormalities such as inv(14)(q11q32) inversion or t(14;14)(q11;q32), t(7;14)(q35;q32) translocations are frequently observed in T-PLL, a rare form of mature T-cell proliferation, in chronic and acute T-cell leukemias arising in patients with the immunode®ciency syndrome of ataxia telangiectasia (AT), and in nonmalignant clonal expansion of T cells in patients with AT (Brito-Babapulle and Catovsky, 1991) . By placing the breakpoints at 14q32.1 that are involved in T-cell neoplasms on the map of the region, we found that the breakpoints form two clusters. The t(14;14) translocations found in AT patients were always associated with an inversion duplication event between the 14q32.1 and 14q32.3 regions (Brito-Babapulle and Catovsky, 1991; Narducci et al., 1995; Russo et al., 1989) , while on the other hand the t(14;14) translocation found in T-PLL is a simple balanced translocation (Mengle-Gaw et al., 1987; Smith et al., 1989) . With respect to the orientation of enhancer element that locates 3' to the constant region of TCR, the centromeric region is involved in inversions, while the telomeric region is only involved in simple translocations (Figure 1 ). These two clusters bracket a segment of approximately 160 kb. We postulated that if the oncogene activated by these dierent rearrangements is the same, it must reside between the two clusters of breakpoints. Within this region, we have previously identi®ed two genes named TCL1 and TML1 that are activated and deregulated by chromosomal translocations and inversions (Sugimoto et al., 1999; Virgilio et al., 1994) . The sequences of the TCL1 and TML1 genes are highly homologous to that of the MTCP1 (TypeB1) gene, which is also activated by juxtaposing with the TCRA/D region at 14q11 (Stern, 1996) .
In the course of 5' RACE experiments on the TML1 gene using mRNA derived from a Burkitt's lymphoma cell line (Daudi) with a set of primers corresponding to exon 2 of the TML1 gene (Primers 11 and 12 in Figure  2 and Table 1 ), we isolated two types of cDNA clones. One (pMDAB4) carrying a fragment of 0.3 kb in size encoded exons 1 and 2 of the original TML1 gene. The other (pMDAB1) carrying a fragment of 2.6 kb in size contained exon 2 of TML1 as well as an unknown upstream sequence. To further characterize the structure of this unknown upstream sequence, we performed 5' RACE and 3' RACE experiments using mRNAs from human placenta and the Daudi cell line with a combination of primers derived from this unknown region and the TML1 gene. In the 5' RACE experiment involving placental mRNA with nested primers 3 and 2, we isolated a clone carrying an insert of 1.4 kb further extended 5' to the primer 2. We also obtained four types of cDNA clones each containing a poly(A) + stretch at the 3' end by 3' RACE of placental mRNA with nested primers 4 and 5. The analysis of these cDNA clones revealed that four dierent exons (exons 9, 10, 11 and 12) are involved in transcription termination and poly(A) + addition, as indicated in Figure 2 . We then performed RT ± PCR to obtain cDNA clones coding for each entire transcript using mRNA from placenta and Daudi cells with primers corresponding to either exon 1 or exon 5 and the last exon of each transcript, including TML1. From these experiments, we isolated 11 dierent cDNA clones, Figure 1 Genomic organization of the TCL6, TML1, and TCL1 genes. (a) Restriction map of the TCL6, TML1, and TCL1 loci on chromosome 14q32.1. Vertical arrows, cloned breakpoints in the literature (Davey et al., 1988; Mengle-Gaw et al., 1987 Russo et al., 1989; Smith et al., 1989) 
namely A1, A2, A3, B1, C1, D1, E1, F1, F2, F3 and F4 as illustrated in Figure 2 . The sequence analysis of each cDNA clone revealed that ®ve open reading frames (ORFs) can be totally predicted. The A, B, C, and D type transcripts can potentially code proteins of 141, 105, 119, and 163 amino acids, respectively. Thus, we designated these proteins ORF141, ORF105, ORF119, and ORF163, respectively (Figure 2) . The E The ®ve predicted open reading frames (ORF72, ORF105, ORF119, ORF141, and ORF163) are indicated by solid bars. The arrows indicate two clones ®rst isolated by 5' RACE experiment using Daudi mRNA. The TCL6 cDNA was synthesized from 1 mg of poly(A) { RNA from human placenta or Burkitt's lymphoma cell line (Daudi). The 5' RACE and 3' RACE experiments were performed by using a Marathon cDNA ampli®cation kit (Clontech, Palo, Alto, CA, USA) according to the manufacture's recommendations. The conditions for PCR were: denaturing for 1 min at 958C, annealing for 1 min at 558C, and elongation for 2 min at 728C (20 ± 30 cycles). The ampli®ed products were subcloned into a pNoTA/T7 vector using a Prime PCR Cloner kit (5 prime ? 3 prime, Inc), and sequenced by the dideoxynucleotide chain-termination method. Both strands of the cDNA clones were sequenced Identification of TCL6 gene near TML1 locus M Saitou et al type transcript utilized exon 11 as the last exon. In addition, we found F type transcripts that are fusion transcripts between this newly identi®ed gene, named T-cell leukemia/lymphoma 6 (TCL6), and the TML1 gene. There were four types of fusion transcripts, F1, F2, F3 and F4. As shown in Figure 2 , these fusion transcripts can potentially encode two types of ORFs, one is the common type of ORF found in the TCL6 gene (such as ORF141 and ORF 105), and the other is ORF72. The latter, which is located within exon 4 of the TML1 gene, utilizes a dierent frame from the TML1 protein, and it is common to all types of fusion transcripts. Although the ORF is rather short, the sequence surrounding the translation initiation codon of ORF72 satis®es the Kozack consensus.
To determine whether these ®ve ORFs are actually capable of coding proteins in mammalian cells, we expressed these ORFs in COS7 cells by fusing green uorescence protein (GFP) at the carboxyl terminus of each ORF. We ®rst constructed a control expressionplasmid of GFP (pSRa/GFP) and ®ve expression plasmids (pEF1/ORF163GFP, pEF1/ORF141GFP, pEF1/ORF119GFP, pEF1/ORF105GFP and pEF1/ ORF72GFP) designed to code each ORF-GFP fusion protein, as shown in Figure 3a . Each construct contained at least 100 bp of the 5' noncoding region together with an in-frame stop codon corresponding to each ORF to assure an intact translation-initiation of each ORF. Each construct was transfected into COS7 cells, and GFP signals were observed 48 h later by microscopy.
In the transfected cells,¯uorescent signals each with a distinct localization were observed from all constructs tested. ORF141GFP was detected as a granular cytoplasmic¯uorescence around the nucleus, while ORF163GFP, ORF119GFP, and ORF105GFP showed identical localization, each being detected as a stronḡ uorescence in the nucleus together with a weak signal in the cytoplasm (Figure 3b-5 and 6 ). Although further experiments are required, this nuclear localization of ORF163GFP, ORF119GFP and ORF105GFP may be due to the putative nuclear localization signal (RRGDHAKDK) located in exon 6d, which is common to these ORFs. Moreover, ORF72GFP was also detected as cytoplasmic¯uorescence. In about 30% of cells, a cluster of strong¯uorescence was observed in part of the cytoplasm (data not shown). Since ORF141 and ORF105 always preceded ORF72 in an F-type transcript, we then asked whether ORF72 can be translated in the presence of ORF141 and ORF105 in the same transcript. We constructed two additional expression plasmids (pEF1/ORF141-72GFP and pEF1/ORF105-72GFP) derived from the F1 or F4 type transcripts, as shown in Figure 3a . In transfected cells, both ORF141-72GFP and ORF105-72GFP showed the same localization as ORF72GFP, although (Figure 3b-7 and 8 ). These results indicated that the ORF72 in F-type transcripts is indeed capable of producing protein.
To explore the mechanism responsible for the transcriptional diversity, we isolated and sequenced subclones corresponding to the entire TCL6 gene from P1 clones (P1 7-4 and P1 20-7) (Virgilio et al., 1993) . The map and structure of the TCL6 gene are shown together with those of the TML1 and TCL1 genes in Figures 1 and 2 . The TCL6 locus maps 7 kb centromeric to the TML1 locus with a tail-to-head orientation. The TCL6 gene is composed of at least 12 exons with small alternative exons. Donor and Figure 4 Expression of TCL6, TML1, and TCL1 genes. (a) Northern blot analysis of TCL6 transcripts in normal tissues. Upper panel: hybridization to pTCL6ORF163 cDNA. Lower panel: hybridization to a human b-actin probe. (b) RT ± PCR analysis of TCL6, TML1, TCL1, CD4, CD8, CD14, CD19 and G3PDH genes in human leukocytes using the Human Blood Fractions MTC TM Panel (Clontech, Palo Alto, CA, USA) with a set of primers (primers 4 and 6, primers 4 and 13, primers 10 and 11, primers 15 and 16, primers 19 and 20, primers 21 and 22, primers 23 and 24, primers 25 and 26, and primers 17 and 18 for TCL6, TCL6-TML1 fusion transcripts, TML1, TCL1, CD4, CD8, CD14, CD19 and G3PDH genes, respectively). (c) RT ± PCR analysis of the TCL6, TML1 and TCL1 genes in tumor cell lines (left panels) and normal tissues (right panels). First row, TCL6 primers 4 and 6; second row, TML1 primers 10 and 11; third row, TCL1 primers 15 and 16; fourth row, control G3PDH primers 17 and 18. (d) RT ± PCR analysis of the TCL6-TML1 fusion transcripts in tumor cell lines (left panels) and normal tissues (right panels). Top, TCL6 and TML1 primers 4 and 13; bottom, control G3PDH primers 17 and 18. The TCL6 isoforms corresponding to each band are indicated on the right. Human Multiple Tissue Northern (MTN) TM Blot (Clontech) was hybridized with a 32 P-dCTP-labeled probe overnight at 428C in ULTRAhyb TM Ultrasensitive Hybridization Buer (Ambion, Austin, Texas, USA). The ®lter was washed twice in 26SSC, 0.1% SDS at 428C for 10 min, twice in 0.16SSC, 0.1% SDS at 428C for 10 min. The ®lter was then subjected to autoradiography using Kodak X-ray ®lms (Eastman Kodak, Rochester, NY, USA) for 7 days. First-strand cDNA synthesis was performed using 10 mg of total RNA with Superscript II Reverse transcriptase (Life Technologies, Inc., Gaithersburg, MD, USA) and oligo (dT) as a primer. Ampli®cation of each cDNA was carried out using Elongase (Life Technologies, Inc., Gaithersburg, MD) under the following conditions: denaturing for 1 min at 958C, annealing for 1 min at 558C, and elongation for 2 min at 728C (20 ± 30 cycles). The resulting products were visualized by staining with ethidium bromide after fractionation on 1% agarose gel. The speci®city of each ampli®ed product was con®rmed by hybridization with a digoxigenin-labeled exon-speci®c oligonucleotide acceptor signal sequences were not always in good agreement with the consensus signal sequences (Mount, 1982) . Thus, the donor signal sequences at exons 2a, 2b, and 4b were CA, TT, and TT, respectively, instead of GT. The acceptor signal sequences at exons 3 and 10a were AA and GT, respectively, instead of AG. This inaccuracy in splicing signals may contribute to the complexity of transcripts of the TCL6 gene.
We next investigated the expression pro®le of the TCL6 gene in normal tissues and cancer cell lines. The expression of the TCL6 gene was ®rst studied by Northern blot analysis using 32 P-labeled pTCL6ORF163 cDNA as a probe. In normal tissues, three major smeary bands of 5.5, 4.0 and 3.2 kb or 5.5, 4.5 and 4.0 kb in size were detected in kidney and placenta, respectively (Figure 4a ). However, no signal was detected in brain, heart, skeletal muscle, colon, thymus, spleen, liver, small intestine, lung, or peripheral blood lymphocytes, The reason for the ambiguity of each band is most likely the complexity of the TCL6 transcripts. To further investigate the expression pro®le of the TCL6 isoforms carrying the two major ORFs 141 and 105, we performed sensitive RT ± PCR assays of TCL6 using a set of primers corresponding to exons 5 and 8 of the TCL6 gene, and compared the results with those obtained for the TML1, TCL1 and G3PDH genes. Among the normal tissues examined, a high level of expression of TCL6 was observed in placenta and kidney, and a low level in tonsil, spleen, and lymph node. In tumor cells, a high level of expression was observed in a cell line of acute T-lymphocytic leukemia derived from patient NL in Figure 1 with a t(14;14) chromosome translocation in 14q32.1 (SupT 11 (Smith et al., 1989) ), in a Burkitt's lymphoma cell line (Daudi), and in three acute B-lymphocytic leukemia cell lines (SP50, SP53, and B-ALL (Kubonishi et al., 1991)) as well as in a Hodgkin's disease cell line (HD70 (Kanzaki et al., 1992) ). In contrast, no expression was detected in several other postthymic Tcell lines lacking the translocation in 14q32.1, such as Jurkat, SKW-3, and SupT 1 cells (Figure 4c ). Of interest is the fact that no expression was detected in mature CD4+ or CD8+ T-cells even after 35 cycles of ampli®cation; this was in clear contrast to the high level of expression seen in CD19+ B-cells (Figure 4b ) which started to become apparent after 22 cycles of PCR.
To clarify the expression pro®le of the fusion transcript between the TCL6 and TML1 genes, we performed RT ± PCR assays using primers corresponding to exon 5 of TCL6 and exon 3 of TML1, and we compared the results with those obtained for the G3PDH gene. As shown in Figure 4d , RT ± PCR products corresponding to F1, F2, F3, and F4 were mainly observed in B-lineage cells including CD19+ Blymphocytes, Daudi, SP50, SP53, B-ALL, and a Hodgkin's disease cell line (HD70). The fusion transcript was also observed strongly in SupT 11 and weakly in the kidney and glioblastoma cell lines (U118MG, U373MG, U87MG and A1267 (Goswami et al., 1998) ), In contrast, almost no RT ± PCR product was observed in other normal tissues or postthymic Tcell tumors examined, In leukocytes, our results indicate that the TCL6 gene as well as TCL6-TML1 fusion transcripts are mainly expressed in the B-cell lineage and are not expressed in T-cells, and that it becomes deregulated as a consequence of its juxtaposition to the TCRA/D locus (just like the TCL1 oncogene and the candidate oncogene TML1). Although both the oncogenic potential of the TCL6 gene and the signi®cance of the fusion transcripts coding for ORF72 remain to be determined, our results suggested that TCL6 is also a candidate gene potentially involved in leukemogenesis.
Note added in proof After we submitted the present manuscript, Hallas et al. (1999) reported identifying TNG1 and TNG2 genes from the same region as that described here. Although those authors considered TNG1 and TNG2 to be independent genes, our results clearly indicate that TNG1 and TNG2 are isoforms of the TCL6 gene (corresponding to A1 and A3 type transcripts of the TCL6 gene, respectively). Since our sequence corresponding to the translation initiation codon of the TNG2 gene is not ATG but ACG, there is no obvious translation initiation codon within the TNG2 gene. Although further study is required, it is possible that the sequence at the translation initiation codon of TNG2 is polymorphic.
